Kronenfeld Mark A. 4/A

What Happened

• Mark A. Kronenfeld, a director of Pacira BioSciences, was awarded 6,163 restricted stock units (RSUs) on June 11, 2025. The RSUs were granted at $0.00 per unit (no cash exchanged) and represent the contingent right to receive one share of common stock per RSU upon vesting. The award vests on June 11, 2026 if he remains in continuous service through that date.
• This is an equity award (not an open-market purchase or sale) and does not represent immediate share ownership or a cash transaction. The Form 4 was amended to correct the originally reported grant size (originally showed 9,999 RSUs in error).

Key Details

• Transaction date: 2025-06-11; reported in an amended Form 4 filed 2026-03-19 (late filing).
• Transaction type/code: Award/Grant (Code A); number of RSUs: 6,163; reported price: $0.00; total reported value: $0.
• Vesting: RSUs vest on June 11, 2026, contingent on continued service; each RSU converts to one share upon vesting (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing note: This is an amended filing correcting the previously reported 9,999 RSUs down to 6,163.

Context

• RSU grants are prospective compensation and only convert to actual shares if vesting conditions are met; they do not indicate an immediate market purchase or sale.
• The filing was submitted months after the transaction date and required amendment for accuracy, which affects transparency but does not change the underlying grant terms.